The RealBio® Team

Paul Neeb
President and CEO

With a background in management, sales, and finance, Paul has served in a variety of leadership roles at industry leaders Gillette CANADA, Inc., G.D.Searle (a division of Monsanto), The NutraSweet Company (a division of Monsanto), and Pharmacia (purchased by Pfizer in 2003). Most recently, Paul was the Executive in Residence for the SWMF Life Science Fund, a private for-profit $50 Million venture fund supported by Southwest Michigan First (SWMF), a private non-profit encouraging economic growth, job creation, and entrepreneurship in the southwest Michigan region.

Paul holds a Masters in Management from the JL Kellogg Graduate School of Management at Northwestern University and a Honors Bachelor of Commerce from McMaster University in Hamilton, Ontario, Canada.


Bill Pfund
Vice President, Product Development

Bill brings more than 25 years of experience in the pharmaceutical and life science industry to his position at RealBio®. During more than 18 years at Upjohn/Pharmacia/Pfizer, he was responsible for activities spanning the entire drug development continuum including development and validation of cell-based assays supporting the discovery and quality control of biopharmaceuticals. More recently, Bill worked in a contract research organization where he served as Director of immunoassay and biomarker services, Manager of GMP product testing, and Director of Business Development. Bill holds a B.S. (Biology) from the State University of New York, College at Oswego and a M.S. (Microbiology) from The Ohio State University. Bill also received specialized cell and tissue culture training from the W. Alton Jones Cell Science Center in Lake Placid, New York.

Board of Directors

Jack Ball

Jack Ball is President, Tyball Associates, Inc. a consulting company bringing 21st century sales and marketing strategies, that are highly capital efficient, to companies in the biotech tools space. Mr. Ball also serves part-time as a Mentor-in-Residence at the Office of Tech Transfer, University of Michigan where he assists faculty and staff in commercializing the products they have developed in their laboratories. In addition he serves on the board of directors of the following five companies: 3D Biomatrix, IntelliCyt, RealBio Technology, Swift Bioscience and Switchgear Genomics

Mr. Ball has a long and proven record for bringing life science products to market and capitalizing on existing product potential. Most recently he was Chief Commercial Officer at Accuri Cytometers where he developed a novel commercialization model that was highly capital efficient. He and the management team sold the company to Becton Dickinson for $205M in March 2011. Prior to Accuri Cytometers, he was CEO of Amnis Corporation, a venture backed technology start-up developing and selling high-end imaging flow cytometers. He has also served as Chief Commercial Officer for Molecular Probes, Inc., the world leader in reagents for cell analysis, including flow cytometry consumables. Prior to that he was with Orchid Biosciences as Sr. VP and General Manager and with Amersham Pharmacia Biotech Inc., where he rose to President, Region North America and was responsible for sales, marketing, and customer support for all products sold in North America.


Roy Cosan
Managing Director, Fjord Ventures

Roy's experience includes 32 years with Johnson and Johnson. He was Vice President of New Product Development at Janssen Pharmaceutical where he launched Risperdal and Reminly. Roy was also a Vice President with the Johnson & Johnson Development Corp., the venture capital arm of J&J where he invested in 19 companies and held 11 board of director seats. At J&J, Roy also built a virtual R&D capability for the J&J Pharmaceutical organization.

Paul Neeb
President and CEO RealBio® Technology, Inc.



Dr. Eugene H. McKay, III

Dr. McKay is currently a Professor of Business and Economics at Kellogg Community College in Battle Creek, Michigan. Prior to his academic career, Gene was Co-President and CEO of Archway Cookies, Inc., that was sold to private investors in 1998.

Dr. John R. Trittschuh M.D.
Eye Care Physicians & Surgeons, P.C.